Investors Buy High Volume of Capricor Therapeutics Call Options (NASDAQ:CAPR)

Capricor Therapeutics Inc (NASDAQ:CAPR) saw some unusual options trading activity on Monday. Traders bought 4,400 call options on the company. This is an increase of 37% compared to the typical daily volume of 3,206 call options.

Capricor Therapeutics Trading Down 11.1 %

CAPR opened at $13.67 on Tuesday. The company’s fifty day moving average price is $14.42 and its two-hundred day moving average price is $13.80. Capricor Therapeutics has a 1-year low of $3.52 and a 1-year high of $23.40. The company has a market cap of $621.57 million, a price-to-earnings ratio of -12.90 and a beta of 4.08.

Analyst Ratings Changes

A number of equities research analysts have recently commented on CAPR shares. Cantor Fitzgerald upped their price objective on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. HC Wainwright reissued a “buy” rating and set a $77.00 target price on shares of Capricor Therapeutics in a research note on Thursday, January 2nd. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $34.50.

Institutional Trading of Capricor Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Summit Investment Advisors Inc. raised its holdings in shares of Capricor Therapeutics by 54.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company’s stock valued at $53,000 after purchasing an additional 1,345 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in Capricor Therapeutics by 22.4% during the fourth quarter. The Manufacturers Life Insurance Company now owns 12,919 shares of the biotechnology company’s stock worth $178,000 after purchasing an additional 2,361 shares during the period. Invesco Ltd. boosted its position in Capricor Therapeutics by 20.5% during the fourth quarter. Invesco Ltd. now owns 14,678 shares of the biotechnology company’s stock worth $203,000 after purchasing an additional 2,500 shares during the period. Russell Investments Group Ltd. boosted its position in Capricor Therapeutics by 172.8% during the fourth quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 2,947 shares during the period. Finally, Corebridge Financial Inc. boosted its position in Capricor Therapeutics by 32.2% during the fourth quarter. Corebridge Financial Inc. now owns 18,212 shares of the biotechnology company’s stock worth $251,000 after purchasing an additional 4,434 shares during the period. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.